A Phase IIb Study to Investigate the Treatment-Sparing Effects of AEROVANT AER 001 Inhalation Powder in Asthma Patients Not Fully Controlled on Current Therapy.

Trial Profile

A Phase IIb Study to Investigate the Treatment-Sparing Effects of AEROVANT AER 001 Inhalation Powder in Asthma Patients Not Fully Controlled on Current Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 May 2015

At a glance

  • Drugs Pitrakinra (Primary)
  • Indications Asthma
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms AEROTRIAL
  • Sponsors Aerovance
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Sep 2011 Planned number of patients changed from 500 to 536.
    • 25 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top